MALDI-MS

With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.

By Adam Bonislawski
Biodesix said this week that it is collaborating with pharma firm Kadmon on a 620-patient Phase III clinical trial of that company's reversible tyrosine kinase inhibitor KD019.

By Adam Bonislawski
Bio-Rad has developed a workflow linking surface plasmon resonance to MALDI mass spectrometry that could offer a more sensitive and streamlined alternative to conventional SPR-MS techniques.

ProteoMonitor spoke to Cristobal Belda-Iniesta, head of the Biomarkers and Experimental Therapeutics for Cancer Group at Madrid's University Hospital La Paz, about his work applying proteomics to guide cancer therapy.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.